The conventional use of high-sensitivity troponins (hs-troponins) is for diagnosing\nmyocardial infarction however they also have a role in chronic disease management. This pilot\nstudy assessed the relationship of hs-troponins with echocardiographic markers of left ventricular\nhypertrophy (LVH) and structural heart disease (SHD). Patients undergoing computer gomography\n(CT) coronary angiogram for low-intermediate risk chest pain and healthy volunteers were recruited.\nHs-troponins Singulex I, Abbott I and Roche T and N-terminal pro-brain natriuretic peptide\n(NT-proBNP) were evaluated in relation to SHD parameters including left ventricular hypertrophy\n(LVHEcho) and left atrial enlargement (LAEEcho) on echocardiography. 78 subjects who underwent\nechocardiography were included in this study. C-statistics (95% confidence interval) of the\nfour biomarkers for predicting LVHEcho were 0.84 (0.72ââ?¬â??0.92), 0.84 (0.73ââ?¬â??0.92), 0.75 (0.63ââ?¬â??0.85) and\n0.62 (0.49ââ?¬â??0.74); for LAEEcho 0.74 (0.6ââ?¬â??0.85), 0.78 (0.66ââ?¬â??0.88), 0.55 (0.42ââ?¬â??0.67) and 0.68 (0.62ââ?¬â??0.85);\nand composite SHD 0.79 (0.66ââ?¬â??0.88), 0.87 (0.75ââ?¬â??0.94), 0.62 (0.49ââ?¬â??0.73) and 0.74 (0.62ââ?¬â??0.84) respectively.\nOptimal cut points for SHD were >1.2 ng/L, >1.6 ng/L, >8 ng/L and >18 pmol/L respectively.\nThese results advocate the potential role of hs-troponins as screening tools for structural heart disease\nwith theranostic implications.
Loading....